Trends in Cancer

Papers
(The TQCC of Trends in Cancer is 20. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
Turning Cold into Hot: Firing up the Tumor Microenvironment543
Circular RNAs in Cancer: Biogenesis, Function, and Clinical Significance382
Senescent Cells in Cancer Therapy: Friends or Foes?242
Glioblastoma Stem Cells: Driving Resilience through Chaos210
3D In Vitro Model (R)evolution: Unveiling Tumor–Stroma Interactions208
Exosomes as a Multicomponent Biomarker Platform in Cancer172
Clinical Development of BRAF plus MEK Inhibitor Combinations164
Cancer Epigenetics, Tumor Immunity, and Immunotherapy163
The Cancer Microbiome: Distinguishing Direct and Indirect Effects Requires a Systemic View156
Necroptosis and tumor progression155
Targeting Glycosylation: A New Road for Cancer Drug Discovery145
Targeting EMT in Cancer with Repurposed Metabolic Inhibitors139
Gut Microbiota in Cancer Immune Response and Immunotherapy131
RNA Splicing and Cancer130
Promoter DNA Hypermethylation and Paradoxical Gene Activation127
MGMT Status as a Clinical Biomarker in Glioblastoma127
Emerging Mechanisms by which EMT Programs Control Stemness121
Advanced Prostate Cancer: Treatment Advances and Future Directions118
Tumour Cell Secretome in Chemoresistance and Tumour Recurrence96
Molecular Tumor Boards in Clinical Practice91
Exosomal PD-L1: Roles in Tumor Progression and Immunotherapy89
Immune Cell-Derived Exosomes in the Cancer-Immunity Cycle88
Extracellular Vesicles in Cancer Detection: Hopes and Hypes85
Better together: circulating tumor cell clustering in metastatic cancer84
Tumor Plasticity and Resistance to Immunotherapy83
Targeting the DNA Repair Enzyme Polymerase θ in Cancer Therapy82
Precision therapy for RET-altered cancers with RET inhibitors82
Enhancing the Efficacy of Glutamine Metabolism Inhibitors in Cancer Therapy81
Hyperprogression and Immunotherapy: Fact, Fiction, or Alternative Fact?80
Targeting ferroptosis in pancreatic cancer: a double-edged sword75
Fat and Furious: Lipid Metabolism in Antitumoral Therapy Response and Resistance74
Tunneling Nanotubes: The Fuel of Tumor Progression?72
Mitochondrial Stress Response and Cancer69
Tweak to Treat: Reprograming Bacteria for Cancer Treatment66
TRAIL of Hope Meeting Resistance in Cancer66
Revisiting the HIF switch in the tumor and its immune microenvironment66
Zebrafish Xenografts for Drug Discovery and Personalized Medicine65
Targeting CAFs to overcome anticancer therapeutic resistance63
Ferroptosis and Photodynamic Therapy Synergism: Enhancing Anticancer Treatment63
From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm59
Targeting SUMO Signaling to Wrestle Cancer58
FTO in cancer: functions, molecular mechanisms, and therapeutic implications56
Targeting the Tumor Microenvironment in Colorectal Peritoneal Metastases55
Pharmacological Targeting of IRE1 in Cancer54
Cirrhosis: A Questioned Risk Factor for Hepatocellular Carcinoma54
Inflammation: the incubator of the tumor microenvironment53
Autophagy Regulates Stress Responses, Metabolism, and Anticancer Immunity53
Metabolic Reprogramming in Anticancer Drug Resistance: A Focus on Amino Acids53
Challenges in glioblastoma research: focus on the tumor microenvironment51
Utilizing chemokines in cancer immunotherapy49
C1q+ macrophages: passengers or drivers of cancer progression49
Targeting the Mevalonate Pathway in Cancer49
The Role of the Microenvironment and Immune System in Regulating Stem Cell Fate in Cancer48
Drug independence and the curability of cancer by combination chemotherapy48
Nanotherapeutics for Antimetastatic Treatment47
NF-κB in the New Era of Cancer Therapy47
Targeting the replication stress response through synthetic lethal strategies in cancer medicine46
Radiotherapy and immunotherapy: open questions and future strategies45
Mutagenesis by Microbe: the Role of the Microbiota in Shaping the Cancer Genome45
Therapeutic targeting of regulatory T cells in cancer45
Coagulome and the tumor microenvironment: an actionable interplay44
Liver Inflammation and Hepatobiliary Cancers44
Antibody–drug conjugates: in search of partners of choice43
Roles and Regulations of TET Enzymes in Solid Tumors43
Extracellular and nuclear PD-L1 in modulating cancer immunotherapy43
The emerging field of oncolytic virus-based cancer immunotherapy42
Alternative Lengthening of Telomeres: Building Bridges To Connect Chromosome Ends42
Targeting CTGF in Cancer: An Emerging Therapeutic Opportunity42
Mechanisms Underlying Recurrent Genomic Amplification in Human Cancers41
Reconciling Non-Genetic Plasticity with Somatic Evolution in Cancer41
Tumor Innervation: Cancer Has Some Nerve41
Emerging Players in Prostate Cancer–Bone Niche Communication40
Next-Generation Liquid Biopsies: Embracing Data Science in Oncology39
Cancer Plasticity: The Role of mRNA Translation39
Evolution of metastasis: new tools and insights39
Towards the Microbial Production of Plant-Derived Anticancer Drugs38
T follicular helper cells in cancer37
The Hippo Pathway as a Driver of Select Human Cancers37
Drilling for Oil: Tumor-Surrounding Adipocytes Fueling Cancer37
The spectrum of sex differences in cancer36
Improving Bioprinted Volumetric Tumor Microenvironments In Vitro36
Nanomedicine-based strategies to target and modulate the tumor microenvironment36
Single cell cancer epigenetics35
Dysregulated Ribosome Biogenesis Reveals Therapeutic Liabilities in Cancer35
Life and Death Decision-Making by p53 and Implications for Cancer Immunotherapy35
Hypertranscription and replication stress in cancer35
How cancer cells make and respond to interferon-I34
Cancer of Unknown Primary in the Molecular Era34
Dark Side of Cytotoxic Therapy: Chemoradiation-Induced Cell Death and Tumor Repopulation33
RAC1 as a Therapeutic Target in Malignant Melanoma33
HLA-G/LILRBs: A Cancer Immunotherapy Challenge33
Co-occurrence and mutual exclusivity: what cross-cancer mutation patterns can tell us32
HLA class I antigen processing machinery defects in antitumor immunity and immunotherapy32
Technical and biological constraints on ctDNA-based genotyping32
Tele-oncology in the COVID-19 Era: The Way Forward?31
Why Great Mitotic Inhibitors Make Poor Cancer Drugs31
Bispecific Antibodies for Triple Negative Breast Cancer31
Targeting Cancer Heterogeneity with Immune Responses Driven by Oncolytic Peptides31
Tumour microenvironment 3D-modelling: simplicity to complexity and back again31
Therapeutic Repurposing of Biguanides in Cancer30
PML Nuclear Body Biogenesis, Carcinogenesis, and Targeted Therapy30
Regulation of extrinsic apoptotic signaling by c-FLIP: towards targeting cancer networks30
Understanding the Cause and Consequence of Tumor Heterogeneity30
Cell death, therapeutics, and the immune response in cancer29
Tissue architecture in tumor initiation and progression29
Mitochondrial DNA is a major source of driver mutations in cancer28
Extracellular ATP and Adenosine in Cancer Pathogenesis and Treatment28
Decoding endoplasmic reticulum stress signals in cancer cells and antitumor immunity27
Pediatric Cancer Models in Zebrafish27
The Dual Role of High Endothelial Venules in Cancer Progression versus Immunity27
Nanotherapeutics for Immuno-Oncology: A Crossroad for New Paradigms27
When breaks get hot: inflammatory signaling in BRCA1/2-mutant cancers27
Microfluidics meets 3D cancer cell migration26
DNA Damage Repair Deficiency in Prostate Cancer25
Stearoyl coenzyme A desaturase-1: multitasker in cancer, metabolism, and ferroptosis25
How Comorbidities Shape Cancer Biology and Survival25
Targeting the Gut Microbiome to Mitigate Immunotherapy-Induced Colitis in Cancer25
Genes that Mediate Metastasis across the Blood–Brain Barrier24
Beyond Kinases: Targeting Replication Stress Proteins in Cancer Therapy24
Human-Derived Model Systems in Gynecological Cancer Research24
Building Diverse Mentoring Networks that Transcend Boundaries in Cancer Research24
Metabolic Plasticity of Neutrophils: Relevance to Pathogen Responses and Cancer24
Chromosomal instability and aneuploidy as causes of cancer drug resistance24
Tackling PARP inhibitor resistance23
Emerging signaling mediators in the anorexia–cachexia syndrome of cancer23
Mechanism and therapeutic potential of tumor-immune symbiosis in glioblastoma23
Age-associated differences in the cancer molecular landscape23
New Roles for Fusobacterium nucleatum in Cancer: Target the Bacteria, Host, or Both?23
T cell exhaustion in malignant gliomas23
Immunity beyond cancer cells: perspective from tumor tissue22
The gut–liver axis: host microbiota interactions shape hepatocarcinogenesis22
The Mystery of Rap1 Suppression of Oncogenic Ras22
Synthetic Lethal Interactions of RECQ Helicases22
Exploiting cancer’s drinking problem: regulation and therapeutic potential of macropinocytosis22
Engineering stem cells for cancer immunotherapy22
Cancer cell adaptability: turning ribonucleoprotein granules into targets22
Group Behavior and Emergence of Cancer Drug Resistance21
Cellular and molecular mechanisms of plasticity in cancer21
Mice Are Not Humans: The Case of p5321
Role of financial toxicity in perpetuating health disparities21
Emerging mechanisms of telomerase reactivation in cancer21
SPAG5: An Emerging Oncogene21
Neuronal and tumourigenic boundaries of glioblastoma plasticity20
Artificial intelligence-guided discovery of anticancer lead compounds from plants and associated microorganisms20
Tumor Excision as a Metastatic Russian Roulette: Perioperative Interventions to Improve Long-Term Survival of Cancer Patients20
GSDME: A Potential Ally in Cancer Detection and Treatment20
Lipid in Renal Carcinoma: Queen Bee to Target?20
The Anticancer Potential of T Cell Receptor-Engineered T Cells20
Emerging metabolomic tools to study cancer metastasis20
0.072283029556274